` QURE (Uniqure NV) vs S&P 500 Comparison - Alpha Spread

QURE
vs
S&P 500

Over the past 12 months, QURE has significantly outperformed S&P 500, delivering a return of 229% compared to the S&P 500's 9% growth.

Stocks Performance
QURE vs S&P 500

Loading
QURE
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
QURE vs S&P 500

Loading
QURE
S&P 500
Difference
www.alphaspread.com

Performance By Year
QURE vs S&P 500

Loading
QURE
S&P 500
Add Stock

Competitors Performance
Uniqure NV vs Peers

S&P 500
QURE
ABBV
AMGN
GILD
VRTX
Add Stock

Uniqure NV
Glance View

Economic Moat
None
Market Cap
825.9m USD
Industry
Biotechnology

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

QURE Intrinsic Value
18.06 USD
Undervaluation 16%
Intrinsic Value
Price
Back to Top